BiomEdit Secures USDA Conditional Licensure for First Genetically Engineered Probiotic Biologic Licensed in Any Animal Species

The USDA Center for Veterinary Biologics has granted conditional licensure to BiomEdit’s lead candidate CPerf LLV, a programmable veterinary biologic engineered against Clostridium perfringens toxins — achieved in just over four years from the company’s founding, and believed to be the first genetically engineered probiotic biologic licensed for use in any animal species worldwide.

BCPerf LLV — Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector, previously referred to as BE-101 — received conditional licensure based on the demonstration of a reasonable expectation of efficacy in reducing necrotic enteritis-associated mortality in broiler chickens challenged with Clostridium perfringens.
USDA conditional licensure enables earlier market access for products that demonstrate safety and a reasonable expectation of efficacy, helping address animal diseases with limited treatment options while additional data are generated for full licensure. BiomEdit will continue advancing the product toward full licensure, at which point it is expected to assume the brand name Optavant.
The pivotal efficacy study reviewed by USDA CVB demonstrated a 48.7% reduction in necrotic enteritis-associated mortality, from 13.1% in challenged controls to 6.6% in birds receiving CPerf LLV. Separately, results published in npj Biofilms and Microbiomes showed that in a controlled study of subclinical necrotic enteritis, probiotic-delivered nanobodies targeting alpha toxin and NetB improved broiler weight gain and feed conversion, outperforming both prophylactic antibiotics and the parent probiotic strains. That published data was not reviewed by USDA as part of the conditional licensure process.

The commercial opportunity is substantial. A widely cited industry analysis estimates necrotic enteritis costs the global broiler industry up to $6 billion annually in production losses and control measures. BiomEdit has initiated a commercial evaluation programme with three major US poultry producers, with CPerf LLV expected to be deployed in more than 35 million broilers.

Chief executive Aaron Schacht described the licensure as a defining moment for BiomEdit and for animal health, noting the company had advanced from an ambitious scientific vision to a conditionally licensed product in just over four years, and that the milestone validates the belief that programmable biologics can fundamentally expand what is possible in animal health.

Chief commercial officer Andrew Carlson said the evaluation trials give producers the opportunity to see how the product performs in their own systems — particularly important for a novel biologic technology — with the goal of providing a practical, scalable, non-antibiotic tool for a disease where solutions are needed.

The conditional license is held by Diamond Animal Health, BiomEdit’s contract development and manufacturing partner. Brett Wong of Anterra Capital said achieving conditional licensure demonstrates the team’s ability to translate breakthrough science into commercial products.

BiomEdit has separately initiated its Series C financing round, funding commercial launch, the path to full licensure and expansion of its Programmable Veterinary Biologics platform. The company acquired Folium Science’s technology platform and pipeline assets in August, including BiomElix One and the Guided Biotics CRISPR-Cas technology.